Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Titel:
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Auteur:
Hose, Dorothea Schreder, Martin Hefner, Jochen Bittrich, Max Danhof, Sophia Strifler, Susanne Krauth, Maria-Theresa Schoder, Renate Gisslinger, Bettina Einsele, Hermann Gisslinger, Heinz Knop, Stefan